A 6.5-year-old female Boxer was euthanized and presented for necropsy following rapid clinical decline concomitant with the development of numerous tumor masses. The largest of these masses was in the same location as a mast cell tumor that had been previously removed from this dog. Gross examination revealed the presence of nodules 5-200 mm in diameter throughout the body, including the lymph nodes. Histologic analysis showed an influx of round cells with no granules, leading to the provisional diagnosis of systemic lymphosarcoma. Immunohistochemical staining for B-and T-lymphocyte antigens was negative. Molecular tests were used to identify a tandem duplication in the c-KIT proto-oncogene from both the earlier mast cell tumor and the current nodules, implicating a common origin. Addition of molecular testing to conventional necropsy evaluations allowed a definitive diagnosis of mast cell tumors.
Mast cell tumors, or mastocytomas, are one of the most common types of skin cancer seen in dogs, accounting for an estimated 7-21% of all cases. 3, 10, 17 Although mast cell tumors are rare and generally nonthreatening in humans, 17 they are often more aggressive and constitute a significant health risk in dogs. Canine mast cell tumors develop swiftly, are quick to metastasize, and frequently recur after having been removed. 17 Moreover, certain breeds such as the Boxer appear to have some predisposition toward their development. 3 To investigate the possibility that the Boxer breed has an inherited increased susceptibility to certain types of cancer, particularly mast cell tumors, cases of mast cell tumors in Boxers were solicited and examined. A 6.5-year-old female Boxer had a growth removed from the left shoulder in April 1998. This growth was diagnosed as a grade II mast cell tumor by routine histopathologic analysis. In early 1999, numerous additional nodules developed rapidly over the entire body in a matter of a few weeks, according to the owner and the veterinarian, and the dog was euthanized. The body was frozen and placed in storage until it could be transferred to Michigan State University, after which it was thawed for study. Postmortem examination revealed multiple round to oval nodules 10-30 mm in diameter on the skin of the medial and caudal thighs, perineal region, humerus, femur, and thoracic and abdominal walls. Subcutaneous nodules 10-50 mm in diameter were found in the inguinal region ( Fig. 1A) . Multiple nodules 10-20 mm in diameter were present in the lateral and caudal musculature of the hip. A very large mass about 200 mm in diameter was found in the left subscapular region, approximately the same site from which the original mast cell tumor had been removed; this mass extended deep into the thoracic musculature. Nodules 5-30 mm in diameter were also found in the heart (Fig. 1B) , liver (Fig. 1C ), kidney (Fig. 1D) , and lungs. The mesenteric and mediastinal lymph nodes were enlarged. Samples of nodules from the skin, liver, a lymph node and samples from the large subscapular mass were taken for both microscopic examination and molecular studies.
Histologic examination of the nodules revealed a diffuse infiltration of medium-size neoplastic round cells with large hyperchromatic nuclei. The normal architecture of the lymph node was obliterated by infiltration of neoplastic cells. The mitotic index was moderate, with an average of 5 mitoses/ high-power field. No eosinophils were observed during the microscopic examination. Special stains (Giemsa, toluidine blue) were used, and no mast cell granules were identified (Fig. 2 ). The absence of granules in sections stained with hematoxylin and eosin and with special stains and the extent and pattern of nodules found during the gross examination resulted in a preliminary diagnosis of malignant round cell tumor, highly suggestive of systemic lymphosarcoma. For confirmation, immunohistochemical immunophenotyping for B and T lymphocytes was performed. Formalin-fixed, paraffin-embedded sections of neoplastic tissues were tested. Monoclonal antibodies to CD79a for B lymphocytes and polyclonal antibodies to CD3 for T cell lymphocytes were used, with negative results. Molecular testing was therefore utilized in an attempt to clarify the diagnosis.
Tissue samples from the same nodules used for microscopic examination and a sample of spleen that appeared to contain only normal tissue were chosen to search for potential mutations in the juxtamembrane domain of c-KIT. The c-KIT gene encodes for a receptor tyrosine kinase that is required for the proper development, survival, and maturation of hematopoietic stem cells, melanocytes, and mast cells. 2, 12, 18 The receptor consists of an extracellular domain of 5 immunoglobulin-like folds and an intracellular kinase domain separated by transmembrane and juxtamembrane domains. 11, 19 Point mutations, deletions, and duplications have been identified in the juxtamembrane domain of c-KIT in certain canine mast cell tumors and mast cell tumor cell lines. 6, 8 Some of these changes have been shown to result in constitutive activation of c-KIT in the absence of binding of its normal ligand, alternatively known as Steel factor, mast cell growth factor, or stem cell factor. 2 Activating mutations have also been identified in both human 4 and rodent [14] [15] [16] mast cell tumor cell lines and in situ in cases of human mastocytosis associated with other disorders. 7,9 Similar mutations cause factor-independent cell growth and aggressive behavior characteristic of tumor formation in murine cell lines. 5 Molecular characterization of normal and tumor tissue from this dog was carried out as follows. A guanidiniumbased solution (Trizol a ) was used for the isolation of genomic DNA and total RNA from fresh tissue, following the manufacturer's protocol. Contaminating genomic DNA was removed from the RNA preparation by treatment with RNase-free DNase as previously described. 13 The sample was precipitated in ethanol and resuspended in deionized water to the same volume originally obtained from the extraction procedure. The RNA was then reverse transcribed using random hexamers as primers. A reaction mixture was prepared containing 10 mM DTT, 2.4 g of random hexamers, 0.32 mM dNTPs, 1ϫ first-strand buffer, a 8 l of RNA, and 800 U of Moloney murine leukemia virus reverse transcriptase a in 100 l total volume. All reagents except the first-strand buffer and enzyme were combined and incubated at 70 C for 5 minutes to denature the RNA secondary structure and then placed on ice for 5 minutes. The buffer and enzyme were then added, and the entire mixture was incubated for 1 hour at 37 C, followed by inactivation at 90 C for 5 minutes.
Primers were designed for polymerase chain reaction (PCR) amplification of the juxtamembrane domain of c-KIT based upon the published canine sequence (GenBank no. AF099030). 6 Amplifications were performed with the forward primer 5Ј-CAAATCCATCCCCACACCCTGTTCAC-3Ј and the reverse primer 5Ј-CACTTTCCCGAAGGCAC-CAGCACCCA-3Ј. PCR reactions were in a total volume of 25 l consisting of 1ϫ PCR buffer, a 1.5 mM MgCl 2 , 0.2 mM dNTPs, 20 pmol of each primer, 0.625 U of Taq polymerase, a and either 3 l of cDNA template or 5 l of genomic DNA template. Cycling conditions included an initial denaturation of 4 minutes at 95 C followed by 35 cycles of 95 C for 1 minute, 66 C for 2 minutes, and 72 C for 3 minutes and a final polymerization step of 8 minutes at 72 C. The expected size of the amplified fragment was 267 bp from cDNA and 645 bp from genomic DNA.
Amplified products were separated on 2% agarose gels in Tris-acetate-ethylenediaminetetraacetic acid (EDTA) buffer and purified using a commercial gel extraction kit. b Extracted bands were eluted in 30 l of 10 mM Tris (pH 8), and 5 l was used for manual sequencing using a commercial dideoxy kit with 33 P-radiolabeled terminators, c using the manufacturer's protocol. For the cDNA fragments, the same primers used for PCR amplification were used for the sequencing. For the genomic DNA templates, an additional internal primer, 5Ј-GAGGAGATCAATGGAAACAA-3Ј, was used to sequence the entire fragment. For archived tumors, a slight modification of a microwave-based lysis method 1 was used to extract DNA. A sample of approximately 1-3 mm 3 was removed from each paraffin block and placed into 400 l of a solution of 50 mM Tris (pH 8.5), 1 mM EDTA, and 0.5% Tween. The samples were heated to 95 C for 10 minutes and then microwaved twice for 30 seconds each, with vortexing between each heating step. The samples were allowed to cool, and 75 g of proteinase K was added to each. After incubation overnight at 42 C, the enzyme was inactivated by heating to 95 C for 10 minutes. The samples were centrifuged for 10 minutes at 12,000 rpm in a microcentrifuge, and the supernatant was transferred to a clean tube. The amount of DNA obtained was variable; therefore, multiple dilutions of each sample were tested until PCR was successful. Typical samples amplified correctly at a 1:25 or 1:50 dilution of the original DNA. This diluted DNA was used for PCR and sequencing as described for DNA from fresh tissue.
Amplification of both cDNA and genomic DNA templates from normal tissue produced a single band of the expected size, whereas tumor tissue produced 2 bigger bands in addition to the expected band, approximately 30 and 50 bp bigger than expected (Fig. 3) . In both cDNA and genomic DNA templates, sequencing of the band from normal tissue confirmed that it contained the normal canine sequence. Sequencing of the 3 bands obtained from tumor tissue determined that they represented 1) the normal sequence, 2) a sequence with a 45-bp tandem duplication, and 3) a mixture of the 2 sequences. The duplication was similar to those previously seen in canine mast cell tumors and in approximately the same location, consisting of bases 1721-1765, as per the canine c-KIT sequence. 6 This finding suggested that the tumor in the presented case was a mast cell tumor rather than a lymphosarcoma, as initially diagnosed.
To test the possibility that such mutations might also occur in lymphosarcomas, paraffin-embedded samples of mast cell tumors and lymphosarcomas, including the original mast cell tumor from the Boxer, were selected from the archives in the Animal Health and Diagnostic Laboratory at Michigan State University. RNA was not obtainable from the tissue blocks; therefore, only genomic DNA was studied for these cases. A total of 31 lymphosarcomas and 15 mast cell tumors were successfully amplified. None of the lymphosarcomas contained duplications in this region of c-KIT; however, 2 of the mast cell tumors, including the original mast cell tumor from the Boxer, had tandem duplications. The duplication from the original Boxer tumor was identical to that from fresh tissue in the tumor nodules. It is not known whether or not this particular duplication causes constitutive activation of c-KIT; however, it appears that duplications in this region can be used as markers to positively identify mast cell tumors in some cases, regardless of their implication as the cause of the tumor.
The results suggest that the tumor and nodules in this Boxer represent a highly undifferentiated and aggressive mast cell tumor that resembles systemic lymphosarcoma. Highly undifferentiated grade III mast cell tumors have a significantly decreased number of granules; 17 however, the granules in the present tumors were completely absent. To rule out the possibility that the absence of granules was due to the freezing and thawing process and was not the original state of the tumor, a sample from a newly diagnosed mast cell tumor was subjected to similar conditions of freezing and thawing. No change in granule content was observed in this sample tumor even after 2 months of storage in the freezer, indicating that the tumor in this Boxer most likely never contained granules. Because the presence of granules is often key in the identification of mast cell tumors, it is reasonable to assume that the tumor could have been mistyped as a lymphosarcoma. However, the lymphocyte antigen staining results brought this diagnosis into question. Molecular tests appear to have produced a definitive determination of the actual tumor type seen in this dog. Because the duplication was only seen in tumor DNA and not in normal constitutive DNA, it must have arisen de novo in the tumor and was not an inherited trait. Because it is highly unlikely that 2 independent events would produce identical mutations in 2 different cell types; the current tumors must have been derived from the original tumor and therefore are mast cell tumors.
This case illustrates a potentially beneficial role for the use of molecular tests to aid in diagnosis when the results of conventional tests are in question. The exact test used in this study represents a rare situation that could not occur in all cases because it entailed the identification of a mutation and the availability of a sample from a primary tumor that had been definitively identified. However, results from a larger scale study currently underway appear to indicate that duplications such as that seen in this dog may be common in the more highly aggressive mast cell tumors, suggesting that molecular tests might be useful in these particular cases if the diagnosis is in doubt, even without a previous tumor for comparison. Furthermore, molecular testing may be useful as an adjunct prognostic indicator and may be important in determining therapeutic options. However, such applications will require further studies. With the increasing number of genetic alterations known or suspected to cause neoplasms, the identification of many different tumor types could be facilitated in the near future by molecular testing.
